INHA and tuberculosis: Recently, the TBNET and RESIST-TB networks claimed that the identification of mutations in the rpoB, katG, inhA, embB, rrs, rpsL and gyrA genes of MTB clinical isolates had implications for the management of TB patients and complemented drug susceptibility testing (DST) [19].